Changes in p53 expression, apoptosis and cell proliferation after treatment with 4-hydroxyaminoquinoline 1-oxide (4HAQO) were investigated in the rat pancreas and liver, target and nontarget organs for tumorigenesis, respectively. Male rats were given a single intravenous injection of 4HAQO at a dose of 20 mg/kg body weight and control rats received vehicle alone and were euthanized after 2—72 hours. Pancreata and livers were removed for histopathological examination, immunohistochemistry for p53 protein, PCNA and Ki-67, and TUNEL labeling and electron microscopic observation for detecting apoptosis. In the pancreas, p53 expression and apoptosis were significantly increased first at 4 and 6 hours, respectively, while no change was evident in the liver. The rates peaked at 24 hours, consistent with the peak for PCNA-labeling, while Ki-67-labeling rates peaked at 72 hours. Electron microscopically, apoptotic changes in pancreatic acinar cells were observed after 2 hours. No significant apoptosis, p53 expression or cell proliferation were noted in the pancreatic tissues of the control rats nor in liver cells regardless of 4HAQO treatment. Taken together with our previous data, the results suggest that apoptosis, p53 expression, and enhanced cell replication are closely related phenomena involved in the carcinogenesis of 4HAQO following DNA adduct formation.
Anderson CW (1993). DNA damage and DNA-activated protein kinase. TIBS18: 433—437.
2.
Baas IO, Muldér JR, Offerhaus JA, Vogelstein B., Hamilton SR (1994). An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol172: 5—12.
3.
Coats P., Save V., Ansari B., Hall PA ( 1995). Demonstration of DNA damage/repair in individual cells using in situ end labelling: association of p53 with site of DNA damage. J Pathol176: 19—26.
4.
Donehower LA , Bradley A. (1993). The tumor suppressor p53. Biochem Biophys Acta1155: 181—205.
5.
Doolittle DJ , McKarns SC, Ayres PH, Bombick DW (1992). Molecular approaches for quantifying DNA synthesis and cell proliferation during rodent bioassays . Toxicol Meth1: 215—230.
6.
Galiègue-Zouitina S., Bailleul B., Loucheux-Lefebvre MH (1985). Adducts from in vivo action of the carcinogen 4-hydroxyaminoquinoline 1-oxide in rats and from in vitro reaction of 4-acetoxyaminoquinoline 1-oxide with DNA and polynucleotides. Cancer Res45: 520—525.
7.
Gavrieli Y., Sherman Y., Ben-Sasson SA (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol119: 493—501.
8.
Gerdes J., Lemke H., Baisch H., Wacker HH, Schwab U., Stein H. (1984). Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol133: 1710—1715.
9.
Greenblatt MS , Bennet WP, Hollstein M., Harris CC (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis . Cancer Res54: 4855—4878.
10.
Hainaut P., Milner J. (1993). Redox of p53 conformation and sequencespecific DNA binding in vitro. Cancer Res53: 4469—4473.
11.
Hall PA, McKee PH, Merage HD, Dover R., Lane DP ( 1993). High levels of p53 protein in UV-irradiated normal human skin. Oncogene8: 203—207.
12.
Hall PA, Lane DP ( 1994). p53 in tumor pathology: can we trust immunohistochemistry revisited. J Pathol172: 1—4.
13.
Harris CC (1993). p53: at the crossroads of molecular carcinogenesis and risk assessment. Science262: 1980—1981.
14.
Hayashi Y., Hasegawa T. (1970). Nucleolar alterations of alveolar epithelial cells in rats following a single injection of 4-nitroquinoline 1-oxide. Gann61: 347—352.
15.
Hayashi, Y.Hasegawa T. (1971). Experimental pancreatic tumors in rats after intravenous injection of 4-hydroxyaminoquinoline 1-oxide . Gann62: 329—330.
16.
Hayashi Y., Furukawa H., Hasegawa T. (1972). Pancreatic tumors in rats induced by 4-nitroquinoline 1-oxide derivatives. In: Topics in Chemical Carcinogenesis , Nakahara W, Takayama S, Sugimura T, Odashima S (eds). University Park Press , Baltimore, pp 53—72.
17.
Imazawa T., Nishikawa A., Shibutani M., Ogasawara H., Furukawa F., Ikeda T., Suda K., Hirose M. (2001). Induction of pancreatic islet cell tumors in rats by repeated intravenous administration of 4-hydroxyaminoquinoline 1-oxide . Toxicol Pathol29: 320—327.
18.
Imazawa T., Nishikawa A., Tada M., Takahashi M., Hayashi Y. (1995). Nucleolar segregation as an early marker for DNA damage; an experimental study in rats treated with 4-hydroxyaminoquinoline 1-oxide. Virchows Arch426: 295—300.
19.
Kastan MB, Onyerkwere O., Sidransky D., Vogelstein B., Craig RW (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res51: 6304—6311.
20.
Kelman Z. (1997). PCNA: structure, functions and interactions. Oncogene14: 629—640.
21.
Kemp CJ (1995). Hepatocarcinogenesis in p53-defiecient mice. Mol Carcinogen12: 132—136.
22.
Kisilevsky R. (1974). Hepatic nuclear and nucleolar changes in amanita poisoning. Arch Pathol97: 253—258.
23.
Konishi Y., Maruyama H., Mii Y., Miyauchi Y., Yokose Y Masuhara K. (1982). Malignant fibrous histocytomas induced by 4-hydroxyaminoquinoline 1-oxide in rats. J Natl Cancer Inst68: 859—865.
24.
Lane DP, Benchimol S. (1990). p53: oncogene or anti-oncogene. Genes Dev4: 1—8.
25.
Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. (1993). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature362: 847—849.
26.
Miller EC (1978). Some current perspectives on chemical carcinogensis in humans and experimental animals: Presidential address. Cancer Res38: 1479—1496.
27.
Milne DM, Campbell DG, Caudwell FB, Meek W. ( 1994). Phosphorylation of the tumor supressor protein p53 by mitogen-activated protein kinases. J Biol Chem269: 9253—9260.
28.
Mori K., Ohta A., Murakami T., Tamura M., Kondo M., Ichimura H. (1969). Carcinomas of the glandular stomach and other organs of rats by 4-hydroxyaminoquinoline 1-oxide hydrochloride. Gann60: 627—630.
29.
Mosner J., Deppert W (1994). p53 and mdm2 are expressed independently during cellular proliferation. Oncogene9: 3321—3328.
30.
Nakagawa K., Tada M., Morita T., Utsunomiya J., Ishikawa T. (1988). Immunohistochemical detection of 4-hydroxyaminoquinoline 1-oxide-DNA adducts in mouse tissues in vivo. J Natl Cancer Inst80: 419—425.
31.
Poirier MC (1981). Antibodies to carcinogen-DNA adducts. J Natl Cancer Inst67: 515—519.
32.
Raff MC (1992). Social controls on cell survival and cell death . Nature356: 398—400.
33.
Rao MS, Upton MP, Subbarao V., Scarpelli DG (1982). Two populations of cells with differing proliferative capacities in atypical acinar cell foci induced by 4-hydroxyaminoquinoline 1-oxide in the rat pancreas. Lab Invest46: 527—534.
34.
Shi SR, Key ME, Kalra KL (1991). Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method forimmunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem39: 741—748.
35.
Shivakumar CV, Brown DR, Deb S., Deb SP (1995). Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol15: 6785—6793.
36.
Sugimura T. (1981). The nitroquinolines. In: Carcinogenesis , Sugimura T (ed). Raven Press, New York, Vol 6, pp 1—153.
37.
Tada M., Kohda KH, Kawazoe Y. (1984). Biomimetic preparation and structure determination of QGI, one of the quinoline-DNA base adducts formed in cells treated with 4-nitroquinoline 1-oxide. Gann75: 976— 985.
38.
Toschi L., Bravo R. (1988). Changes in cyclin/proliferating cell nuclear antigen distribution during DNA repair synthesis. J Cell Biol107: 1623—1628.
39.
van Dierendonck JH, Wijsman JH, Keijzer R., van de Velde Cjh, Cornelisse CJ (1991). Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies . Am J Pathol138: 1165— 1172.
40.
Williams GT (1991). Programmed cell death: apoptosis and oncogenesis. Cell65: 1097—1098.
41.
Yonishi-Rouach E. (1991). Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature352: 345—347.
